Potential Biomarker for Aggressive Prostate Cancer Identified
Credit:Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC),USC Norris Comprehensive Cancer Center, Pancreatic Desmoplasia
Roswell Park Cancer Institute researchers have identified a gene that influences metastasis in prostate cancer, and may help clinicians to identify aggressive prostate tumors before they progress and spread to other organs. They are presenting results of this research today at the American Association for Cancer Research (AACR) Annual Meeting 2017, which continues through April 5 in Washington, D.C.
The 5-year survival rate from prostate cancer has risen to 98%, yet aggressive prostate cancers continue to claim lives. Using an unconventional approach focused on off-target data from two genome-wide RNA interference (RNAi) screens, Roswell Park scientists identified disrupted genes that increased metastasis in both cell cultures and laboratory models of cancer. Henry Withers, a doctoral candidate in the Department of Cancer Genetics, is the first author and Irwin Gelman, PhD, also of the Department of Cancer Genetics, is the senior author of “Characterization of an off-target RNAi genomic screen hit identifies GPRC6A as a novel suppressor of metastatic chemotaxis and invasiveness” (late-breaking poster LB-148), to be presented on Monday, April 3 at 1 p.m. EDT.
Capitalizing on overlapping results from two different genetic screens, the team determined that loss of a particular gene, GPRC6A, caused prostate cancer cells to become more invasive and metastatic. The researchers also identified specific microRNAs, or non-coding RNA molecules, that normally function to turn off production of GPRC6A. The researchers are continuing their investigation with the goal of determining whether GPRC6A and associated microRNAs can be used to predict cancer aggressiveness, thereby identifying aggressive disease early and finding targeted treatments for this potentially deadly prostate cancer.
“This research offers a new understanding into the mechanisms that promote early prostate cancer progression from a relatively non-threatening tumor to more aggressive and deadly metastatic growths,” says Dr. Gelman. “This study may help us to identify new treatment options that can improve survival from metastatic prostate cancer.”
More than 25 teams from Roswell Park Cancer Institute have been invited to present their research at the 2017 AACR annual meeting. The research studies cover the gamut from novel insights into a potential biomarker for glioma and an epigenetic approach to understanding androgen deprivation therapy to a microRNA signature scoring system that may predict bone metastasis in breast cancer.
This article has been republished from materials provided by Roswell Park Cancer Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.